The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2017 | Exploiting signalling pathways involved in CLL to develop novel therapies
Silvia Deaglio, MD, PhD, from University of Turin, Turin, Italy, discusses current drugs on the market for the treatment of chronic lymphocytic leukemia (CLL), including anti-PD1/PDL1 antibodies and lenalidomide. She adds that there are several signalling pathways involved in CLL progression and these are under intense investigation by both pharmaceutical companies and academic researchers with the aim to develop drugs that could inhibit the tumour microenvironment. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.
